AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34210290
Drug: Continue anti-PD-1
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue anti-PD-1 treatment until disease progression/unacceptable toxicity/for at least 2 years in the absence of disease progression/unacceptable toxicity
Trial: 34210290
Drug: Stop treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop treatment
Trial: 34210290
Drug: Continue anti-PD-1
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue anti-PD-1 treatment
Trial: 32969024
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) for patients arriving between 6 and 24 hours with ASPECTS ≥7
Trial: 32969024
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) for patients arriving between 0 and 6 hours
Trial: 33047329
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/day)
Trial: 34463311
Drug: Intranasal corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroids (INCS)
Trial: 32025589
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.05%
Trial: 35403447
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg/day tablet
Trial: 35403447
Drug: Cabozantinib 140
RxNorm normalized name: cabozantinib 140 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 140 mg/day capsules
Trial: 34289471
Drug: High UFNET
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High UFNET rate (>1.75 mL/kg/h)
Trial: 34289471
Drug: Middle UFNET
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle UFNET rate (1.01‐1.75 mL/kg/h)
Trial: 34289471
Drug: Low UFNET
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low UFNET rate (<1.01 mL/kg/h)
Trial: 34289471
Drug: Every 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 1.0 mL/kg/h increase in UFNET rate
Trial: 34289471
Drug: UFNET rates
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFNET rates >1.75 mL/kg/h compared with rates 1.01‐1.75 and <1.01 mL/kg/h
Trial: 37349841
Drug: Pregabalin 50
RxNorm normalized name: pregabalin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 50 mg
Trial: 36912792
Drug: Steroid injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injections
Trial: 35354635
Drug: GelStix nucleus
RxNorm normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GelStix nucleus augmentation device
Trial: 35747962
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus 80 mg/day nano-curcumin capsules
Trial: 33882590
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of aspirin
Trial: 32028085
Drug: Focused ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused ultrasound (FUS) treatment
Trial: 35168840
Drug: Concerns about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concerns about COVID-19 vaccine development and mistrust in vaccines
Trial: 32779057
Drug: SZC 5
RxNorm normalized name: Sildenafil citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SZC 5 g
Trial: 32779057
Drug: SZC 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SZC 10 g
Trial: 32886337
Drug: Vehicle lotion
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle lotion (control)
Trial: 33826709
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 or 300 mg
Trial: 34448273
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (Tacrolimus and Mycophenolate mofetil)
Trial: 33991996
Drug: Esketamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine 0.25 mg/kg
Trial: 35255530
Drug: Esketamine 1
RxNorm normalized name: esketamine 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine 1 mg/kg
Trial: 38526550
Drug: Pneumococcal vaccine
RxNorm normalized name: PNEUMOCOCCAL VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal vaccine
Trial: 32940090
Drug: Tuberculosis vaccine
RxNorm normalized name: Tuberculosis vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuberculosis vaccine
Trial: 32940090
Drug: SARS-CoV-2 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccines (various candidates)
Trial: 32669145
Drug: Clozapine and
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine and paliperidone palmitate combination therapy
Trial: 34373315
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo
Trial: 34183702
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600-1800 mg
Trial: 39652807
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT)
Trial: 34503349
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice daily along with 9 cycles of CyBorD
Trial: 35261932
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (sitagliptin + spironolactone)
Trial: 33632377
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (1000 mg ferric carboxymaltose)
Trial: 34477963
Drug: Refrigerated 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refrigerated 2% lignocaine HCl with 1:100,000 epinephrine (LE) after topical ice application for 15 seconds
Trial: 34477963
Drug: Conventional LE
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional LE infiltration after topical gel application for 1 minute
Trial: 32516227
Drug: 0-Mo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0-Mo (placebo and morphine)
Trial: 36178335
Drug: Vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 20 mg once daily (q.d.)
Trial: 36178335
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg once daily (q.d.)
Trial: 34936739
Drug: Spesolimab (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab (900 mg intravenous dose)
Trial: 33153401
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin (enoxaparin)
Trial: 35437957
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FQs with cephalosporins/macrolides for 1 month
Trial: 32750571
Drug: Heparin lead-in
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin lead-in
Trial: 36347845
Drug: Escitalopram (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10-20 mg)
Trial: 35353979
Drug: Ivermectin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (400 µg per kilogram of body weight) once daily for 3 days
Trial: 35311524
Drug: NTM-1633 (0.033,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTM-1633 (0.033, 0.165, or 0.330 mg/kg)
Trial: 35311524
Drug: NTM-1633 (0.330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTM-1633 (0.330 mg/kg)
Trial: 32144522
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg kg-1 IV‐TXA and 20 mg IV‐DXM
Trial: 35970494
Drug: Standard micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard micronutrient supplement (control)
Trial: 34844929
Drug: Intra‐articular saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra‐articular saline injections
Trial: 34190419
Drug: FDC formulation
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC formulation of bazedoxifene 20 mg and cholecalciferol 8 mg
Trial: 34190419
Drug: Individual component
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual component tablets of bazedoxifene and cholecalciferol
Trial: 35404638
Drug: Moral reconation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moral reconation therapy (MRT)
Trial: 35404638
Drug: Moral reconation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moral reconation therapy (MRT) (per-protocol analysis)
Trial: 35780325
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (60,000 IU of vitamin D3 monthly for 5 years)
Trial: 34225200
Drug: Heat stress
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heat stress + ADP group (HSA, basal diet supplemented with 1,000 mg/kg ADP)
Trial: 35549802
Drug: Thrombopoietin mimetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombopoietin mimetic peptide 0.3 μg/kg
Trial: 35549802
Drug: Thrombopoietin mimetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombopoietin mimetic peptide 1.0 μg/kg
Trial: 36123934
Drug: ISU303 (Agalsidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISU303 (Agalsidase beta), 1 mg/kg dose administered every other week for 6 months
Trial: 34706171
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Itepekimab plus Dupilumab)
Trial: 34684511
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D status above 75 nmol/L
Trial: 34787590
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ST)
Trial: 33939666
Drug: Low-dose Auxora
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Auxora plus standard of care (SOC)
Trial: 32720832
Drug: Probiotics (Bifidobacterium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Bifidobacterium lactis Bi‐07, Lactobacillus rhamnosus HN001, Lactobacillus acidophilus NCFM) with conventional treatment
Trial: 32720832
Drug: Probiotics with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics with conventional treatment
Trial: 32345378
Drug: Opicapone 50
RxNorm normalized name: opicapone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 50 mg
Trial: 32732928
Drug: RCA‐ALSS therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCA‐ALSS therapy with R‐CA model
Trial: 32732928
Drug: RCA‐ALSS therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCA‐ALSS therapy with R‐CA score
Trial: 32732928
Drug: RCA‐ALSS therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCA‐ALSS therapy with R‐CA score of 0-2
Trial: 35050203
Drug: Standardized high-fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized high-fat meal containing 75 g of fat (70% fat)
Trial: 32236212
Drug: Cocoa supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa supplementation (5 g daily, 425 mg of flavanols)
Trial: 32484533
Drug: Tablet-based decision
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based decision support tool prior to 25 weeks' gestation
Trial: 34076601
Drug: Oral ASA
RxNorm normalized name: aspirin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ASA 300 mg
Trial: 34076601
Drug: Intravenous lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lysine acetylsalicylate 150 mg
Trial: 33582692
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block with 2 mg/kg Bupivacaine (Group A)
Trial: 35110315
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg TXA
Trial: 35854106
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation (300 mg once a day for 8 weeks)
Trial: 33308329
Drug: Prompt provision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt provision of clozapine for patients with treatment-resistant schizophrenia
Trial: 33308329
Drug: Universal provision
RxNorm normalized name: STATLOCK UNIVERSAL PLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal provision of cognitive-behavioural therapy for patients at clinical high risk of psychosis
Trial: 32444041
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (500 mg tablet daily)
Trial: 32444041
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch preparation)
Trial: 33736674
Drug: Kai-Hou-Jian spray
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kai-Hou-Jian spray (children’s type)
Trial: 35897081
Drug: MMPR plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMPR plus sub‐dissociative ketamine infusion
Trial: 34787719
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preparation and filling)
Trial: 33216360
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of drug
Trial: 34644317
Drug: Azithromycin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (100 mg for three days, given on four occasions at monthly intervals)
Trial: 37610727
Drug: Written Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written Exposure Therapy (WET)
Trial: 33883876
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of estradiol (E2) and dydrogesterone (DG)
Trial: 38795110
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg twice daily
Trial: 36335914
Drug: Apixaban pharmacokinetics
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban pharmacokinetics
Trial: 34715057
Drug: Infliximab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (10 mg/kg over 2 hours without premedication)
Trial: 34715057
Drug: Second IVIG
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second IVIG (2 g/kg over 8-12 hours)
Trial: 34715057
Drug: IVIG (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (as either first or second treatment)
Trial: 34119470
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous iron therapy
Trial: 34119470
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous iron therapy
Trial: 35438782
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily (cohort 1)
Trial: 35438782
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily + Paclitaxel 80 mg/m2 on days 1, 8, and 15 of each 28-day cycle (cohort 2)
Trial: 35438782
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily + Paclitaxel 80 mg/m2 (cohort 2)
Trial: 35147758
Drug: Cold therapy
RxNorm normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold therapy using Siriraj in-house-developed frozen gloves worn during chemotherapy administration.
Trial: 35147758
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cold therapy).
Trial: 35147758
Drug: Cold therapy
RxNorm normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold therapy using frozen gloves.
Trial: 35194005
Drug: G‐chemo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐chemo
Trial: 32054508
Drug: Nasal saline
RxNorm normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal saline spray followed by a fluorinated steroid spray daily for six months (medical management).
Trial: 35380650
Drug: Hospital-based comprehensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-based comprehensive medication reviews including postdischarge follow-up
Trial: 33271049
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy (CPT) for participants who denied head injuries but reported serious nonhead injuries (NHI).
Trial: 33271049
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy (CPT) for participants who denied any injury (NI).
Trial: 32508213
Drug: Stimulant medication
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medication (methylphenidate)
Trial: 35953245
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg daily
Trial: 32537688
Drug: rHuEPO (epoetin-β;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO (epoetin-β; mean dose 6000 IU per week)
Trial: 32331030
Drug: Deutetrabenazine 12
RxNorm normalized name: deutetrabenazine 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine 12 mg/day, titrating up to a maximum total daily dose of 48 mg/day based on dyskinesia control and tolerability.
Trial: 32278029
Drug: Tongguan Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongguan Capsules (TGC) 4.5 g/d for 6 months
Trial: 32278029
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for MI
Trial: 34996820
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment (Control group)
Trial: 32437192
Drug: Caffeine 1
RxNorm normalized name: caffeine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 1 mg/kg
Trial: 34284351
Drug: Caffeine 2
RxNorm normalized name: caffeine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 2 mg/kg
Trial: 33932130
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg
Trial: 35512918
Drug: Warfarin patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin patients
Trial: 34915738
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase before thrombectomy (combination treatment)
Trial: 35897371
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shockwave therapy (r‐ESWT)
Trial: 32407654
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg·kg‐1)
Trial: 32826171
Drug: HDR-BRT (High-Dose-Rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDR-BRT (High-Dose-Rate Brachytherapy)
Trial: 33383348
Drug: Preoperative chemoradiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiotherapy followed by total mesorectal excision and postoperative chemotherapy (standard arm), N = 623
Trial: 33853802
Drug: Weekly menu
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly menu box delivery service including all ingredients and recipes for morning snack, lunch, and afternoon snack, developed by dietitians and meeting menu planning guidelines.
Trial: 32876405
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg (group T)
Trial: 33342003
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with testosterone replacement therapy plus alternate-day tadalafil (10 mg)